Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Ryan N. Hansen, Kangho Suh, Michael Serbin, Chuck Yonan & Sean D. Sullivan. (2021) Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa. Journal of Medical Economics 24:1, pages 563-569.
Read now
Read now
Alexander S. Wang & Steven A. Gunzler. (2019) Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opinion on Pharmacotherapy 20:13, pages 1659-1670.
Read now
Read now
Zhan-Miao Yi, Ting-Ting Qiu, Yuan Zhang, Na Liu & Suo-Di Zhai. (2018) Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation. Therapeutics and Clinical Risk Management 14, pages 709-719.
Read now
Read now
Jesper Jørgensen, Spiros Servos & Panos Kefalas. (2018) The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Evelyn Walter & Per Odin. (2015) Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. Journal of Medical Economics 18:11, pages 860-862.
Read now
Read now
Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín. (2015) Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 889-911.
Read now
Read now
Evelyn Walter & Per Odin. (2015) Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. Journal of Medical Economics 18:2, pages 155-165.
Read now
Read now
Jens P Reese, Judith Dams, Yaroslav Winter, Monika Balzer-Geldsetzer, Wolfgang H Oertel & Richard Dodel. (2012) Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opinion on Pharmacotherapy 13:7, pages 939-958.
Read now
Read now
Heinz Reichmann & Murat Emre. (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone. Expert Review of Neurotherapeutics 12:2, pages 119-131.
Read now
Read now
Ala I Iaconi, Marliese A Zimmerman, Amit S Kulkarni & Rajesh Balkrishnan. (2008) Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature. Expert Opinion on Pharmacotherapy 9:2, pages 163-174.
Read now
Read now
Articles from other publishers (9)
Ronald Pfeiffer. 2013. Handbook of Parkinson's Disease, Fifth Edition. Handbook of Parkinson's Disease, Fifth Edition
448
465
.
Robert A Hauser, Ann Hsu, Sherron Kell, Alberto J Espay, Kapil Sethi, Mark Stacy, William Ondo, Martin O'Connell & Suneel Gupta. (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. The Lancet Neurology 12:4, pages 346-356.
Crossref
Crossref
Ronald F. Pfeiffer. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease
448
465
.
Judith Dams, Bernhard Bornschein, Jens Peter Reese, Annette Conrads-Frank, Wolfgang H. Oertel, Uwe Siebert & Richard Dodel. (2011) Modelling the Cost Effectiveness of Treatments for Parkinsonʼs Disease. PharmacoEconomics 29:12, pages 1025-1049.
Crossref
Crossref
James Shearer, Colin Green, Carl E. Counsell & John P. Zajicek. (2011) The Use of Decision-Analytic Models in Parkinsonʼs Disease. Applied Health Economics and Health Policy 9:4, pages 243-258.
Crossref
Crossref
Ivar Sønbø Kristiansen, Kerstin Bingefors, Dag Nyholm & Dag Isacson. (2012) Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden. Applied Health Economics and Health Policy 7:3, pages 167-180.
Crossref
Crossref
Dyfrig A. Hughes, Lesley Tilson & Michael Drummond. (2009) Estimating Drug Costs in Economic Evaluations in Ireland and the UK. PharmacoEconomics 27:8, pages 635-643.
Crossref
Crossref
David A Gallagher & Anette Schrag. (2008) Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease. CNS Drugs 22:7, pages 563-586.
Crossref
Crossref
Johan SamantaRobert A Hauser. (2006) Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease. Aging Health 2:2, pages 209-219.
Crossref
Crossref